Microbix Biosystems (TSX:MBX) Debt-to-Equity : 0.24 (As of Mar. 2024)

View and export this data going back to 1992. Start your Free Trial

What is Microbix Biosystems Debt-to-Equity?

Microbix Biosystems's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was C$0.27 Mil. Microbix Biosystems's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was C$6.45 Mil. Microbix Biosystems's Total Stockholders Equity for the quarter that ended in Mar. 2024 was C$27.76 Mil. Microbix Biosystems's debt to equity for the quarter that ended in Mar. 2024 was 0.24.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Microbix Biosystems's Debt-to-Equity or its related term are showing as below:

TSX:MBX' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.23 Med: 0.49 Max: 0.93
Current: 0.24

During the past 13 years, the highest Debt-to-Equity Ratio of Microbix Biosystems was 0.93. The lowest was 0.23. And the median was 0.49.

TSX:MBX's Debt-to-Equity is ranked worse than
59.79% of 1062 companies
in the Biotechnology industry
Industry Median: 0.145 vs TSX:MBX: 0.24

Microbix Biosystems Debt-to-Equity Historical Data

The historical data trend for Microbix Biosystems's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Microbix Biosystems Debt-to-Equity Chart

Microbix Biosystems Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Debt-to-Equity

Get a 7-Day Free Trial

0.66

0.93

0.42

0.23

0.27

Microbix Biosystems Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.28	0.29	0.27	0.25	0.24

Competitive Comparison of Microbix Biosystems's Debt-to-Equity

For the Biotechnology subindustry, Microbix Biosystems's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Microbix Biosystems's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Microbix Biosystems's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Microbix Biosystems's Debt-to-Equity falls into.

Microbix Biosystems Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Microbix Biosystems's Debt to Equity Ratio for the fiscal year that ended in Sep. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.265	+	6.38)	/	24.624
	=	0.27

Microbix Biosystems's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.268	+	6.447)	/	27.756
	=	0.24

Microbix Biosystems (TSX:MBX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Microbix Biosystems Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Microbix Biosystems's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Microbix Biosystems (TSX:MBX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Microbix Biosystems Inc (TSX:MBX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

MBXBF:USA

Address

265 Watline Avenue, Mississauga, ON, CAN, L4Z 1P3

Website

https://www.microbix.com

Microbix Biosystems Inc develops biological products and technologies. The company manufactures and develops cell culture-based biological products and technologies. It has developed and acquired two technologies; Kinlytic and LumiSort. The company's operating segment includes Antigen, QAPs DxTM and Other Includes Kinlytic. It generates maximum revenue from the Antigen QAPs segment. Geographically, it derives a majority of revenue from North America.

Executives

James Stuart Currie

Senior Officer

Microbix Biosystems (TSX:MBX) Headlines

No Headlines